Cargando…
Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience
BACKGROUND: Randomized studies of neoadjuvant (NA) trastuzumab and pertuzumab combined with chemotherapy for HER2-positive breast cancers (BC) have reported pathological complete response (pCR) rates of 39 to 61%. This study aimed to determine the real-world efficacy and toxicity of NA trastuzumab a...
Autores principales: | Hall, Benjamin James, Bhojwani, Ajay Ashok, Wong, Helen, Law, Andrea, Flint, Helen, Ahmed, Eliyaz, Innes, Helen, Cliff, Joanne, Malik, Zaf, O'Hagan, Julie Elizabeth, Hall, Allison, Sripadam, Rajaram, Tolan, Shaun, Ali, Zulfiqar, Hart, Clare, Errington, Douglas, Alam, Farida, Giuliani, Rosa, Mehta, Shaveta, Khanduri, Sheena, Thorp, Nicky, Jackson, Richard, Cicconi, Silvia, Palmieri, Carlo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9262537/ https://www.ncbi.nlm.nih.gov/pubmed/35833190 http://dx.doi.org/10.1155/2022/7146172 |
Ejemplares similares
-
Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex
por: Hao, Yue, et al.
Publicado: (2019) -
Correction: Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex
por: Hao, Yue, et al.
Publicado: (2019) -
Pruritus Related to Trastuzumab and Pertuzumab in HER2+ Breast Cancer Patients
por: Gu, Stephanie, et al.
Publicado: (2023) -
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
por: Bianchini, Giampaolo, et al.
Publicado: (2017) -
Characterization of infections and hypogammaglobulinemia treated with the combination of pertuzumab and trastuzumab
por: Mortimer, Joanne E., et al.
Publicado: (2019)